J9347 – Injection, tremelimumab-actl, 1 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9347
- Long description
- Injection, tremelimumab-actl, 1 mg
- Short description
- Inj, tremelimumab-actl, 1 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- ASC
- Approved for ambulatory surgical centers
- Added
- July 1, 2023
- Last change
- July 1, 2023 – No change
Frequently asked questions
What is HCPCS code J9347?
J9347 is a HCPCS Level II code for injection, tremelimumab-actl, 1 mg.
Does Medicare cover J9347?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9331 – Injection, sirolimus protein-bound particles, 1 mg
- J9332 – Injection, efgartigimod alfa-fcab, 2mg
- J9333 – Injection, rozanolixizumab-noli, 1 mg
- J9334 – Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
- J9340 – Injection, thiotepa, 15 mg
- J9341 – Injection, thiotepa (tepylute), 1 mg
- J9342 – Injection, thiotepa, not otherwise specified, 1 mg
- J9345 – Injection, retifanlimab-dlwr, 1 mg
- J9348 – Injection, naxitamab-gqgk, 1 mg
- J9349 – Injection, tafasitamab-cxix, 2 mg
- J9350 – Injection, mosunetuzumab-axgb, 1 mg
- J9351 – Injection, topotecan, 0.1 mg
- J9352 – Injection, trabectedin, 0.1 mg
- J9353 – Injection, margetuximab-cmkb, 5 mg
- J9354 – Injection, ado-trastuzumab emtansine, 1 mg
- J9355 – Injection, trastuzumab, excludes biosimilar, 10 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.